Version history

{
  "description": "## Mechanistic Overview\nTREM2-Dependent Microglial Senescence Transition starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Background and Rationale** Triggering Receptor Expressed on Myeloid cells 2 (TREM2) represents one of the most significant genetic risk factors for late-onset Alzheimer's disease, with rare loss-of-function variants conferring up to threefold increased risk of dementia. This single-pass transmembrane receptor, exclusively expressed on microglia within the brain, has emerged as a critical regulator of microglial phenotype and function throughout the lifespan. Under physiological conditions, TREM2 promotes microglial survival, proliferation, and phagocytic activity while suppressing inflammatory responses. However, accumulating evidence suggests that the protective functions of TREM2 signaling undergo a fundamental transformation during aging, shifting from neuroprotective to potentially neurotoxic. The concept of microglial senescence has gained considerable traction in recent years, paralleling our understanding of cellular senescence in other tissue types. Aged microglia exhibit hallmarks of senescence including shortened telomeres, increased DNA damage, altered metabolism, and most critically, a senescence-associated secretory phenotype (SASP) characterized by chronic low-grade inflammation. This age-related microglial dysfunction creates a vulnerable brain environment where normal homeostatic responses become dysregulated. The TREM2-dependent senescence transition hypothesis proposes that age-related changes in TREM2 signaling pathways represent a critical mechanistic link between normal brain aging and pathological neurodegeneration, particularly in the context of protein aggregation diseases like Alzheimer's and tauopathies. **Proposed Mechanism** The TREM2-dependent microglial senescence transition involves a complex interplay of age-related molecular changes that fundamentally alter microglial responsiveness to pathological stimuli. In young, healthy brains, TREM2 engagement by endogenous ligands such as phosphatidylserine, sphingomyelin, and apolipoprotein E triggers protective signaling cascades through its adaptor protein DAP12. This leads to activation of spleen tyrosine kinase (SYK), phosphoinositide 3-kinase (PI3K), and downstream effectors including AKT and mTOR, ultimately promoting microglial survival, metabolic reprogramming toward oxidative phosphorylation, and efficient phagocytic clearance of cellular debris and misfolded proteins. During aging, several key changes occur that disrupt this protective signaling network. First, chronic oxidative stress and DNA damage activate the DNA damage response pathway, leading to p53 stabilization and subsequent upregulation of p21 and p16 cell cycle inhibitors. This creates a senescent microglial phenotype characterized by cell cycle arrest and resistance to apoptosis. Simultaneously, age-related changes in lipid composition and membrane dynamics alter TREM2 clustering and signaling efficiency. The accumulation of oxidized lipids and advanced glycation end products interferes with TREM2-ligand interactions, while changes in membrane cholesterol content affect receptor trafficking and surface expression. Crucially, senescent microglia exhibit altered TREM2 signaling that favors inflammatory rather than homeostatic responses. Age-related epigenetic modifications, particularly DNA hypomethylation at inflammatory gene promoters and altered histone modifications, prime these cells for exaggerated responses to danger signals. When senescent microglia encounter amyloid-beta oligomers or tau aggregates, TREM2 engagement triggers predominantly pro-inflammatory pathways through enhanced NF-κB and interferon regulatory factor (IRF) activation, leading to increased production of IL-1β, TNF-α, IL-6, and complement factors rather than efficient phagocytic clearance. **Supporting Evidence** Multiple lines of evidence support the TREM2-dependent senescence transition hypothesis. Keren-Shaul et al. (2017) identified disease-associated microglia (DAM) in mouse models of Alzheimer's disease that exhibit a TREM2-dependent activation profile characterized by downregulation of homeostatic genes and upregulation of phagocytic and inflammatory markers. Importantly, these DAM signatures are more pronounced in aged compared to young mice, suggesting an age-dependent component to TREM2-mediated microglial responses. Transcriptomic analyses by Krasemann et al. (2017) demonstrated that microglia from aged brains show increased expression of senescence markers including p16, p21, and SASP components, with these changes being partially dependent on TREM2 signaling. Furthermore, aged microglia exhibit metabolic dysfunction characterized by impaired oxidative phosphorylation and increased glycolytic activity, changes that parallel those observed in senescent cells from other tissues. Critically, studies using human post-mortem brain tissue have revealed age-related changes in TREM2 expression and processing. Suarez-Calvet et al. (2016) found that cerebrospinal fluid levels of soluble TREM2, generated by metalloproteinase-mediated cleavage, increase with age and are further elevated in preclinical Alzheimer's disease. This suggests that age-related changes in TREM2 processing may contribute to altered signaling and microglial dysfunction. Functional studies have demonstrated that TREM2 deficiency exacerbates age-related cognitive decline and amyloid pathology in mouse models. However, paradoxically, some studies suggest that complete TREM2 loss may be protective in certain contexts, potentially by preventing the formation of dysfunctional senescent microglia that contribute to neuroinflammation. **Experimental Approach** Testing the TREM2-dependent senescence transition hypothesis requires a multi-faceted experimental approach combining in vitro, in vivo, and human studies. Primary microglial cultures from young and aged mice could be used to characterize age-related changes in TREM2 signaling responses to amyloid-beta and tau species. Single-cell RNA sequencing would identify senescence-associated transcriptional signatures and their dependence on TREM2 expression. In vivo studies should utilize aged wild-type and TREM2-deficient mice, as well as conditional TREM2 knockout models that allow for temporal control of receptor expression. Stereotactic injection of pre-formed amyloid or tau fibrils into young versus aged brains would assess age-dependent differences in microglial responses. Advanced imaging techniques including two-photon microscopy could track microglial dynamics and morphology in real-time following pathological challenge. Genetic approaches using senolytic compounds that selectively eliminate senescent cells would test whether removing aged microglia prevents pathological progression. Additionally, pharmacological modulation of TREM2 signaling using receptor agonists or antagonists could determine whether enhancing or blocking specific pathway components influences the senescence transition. Human validation would involve analysis of post-mortem brain tissue from cognitively normal aged individuals and patients with various neurodegenerative diseases, focusing on microglial senescence markers, TREM2 expression patterns, and their correlation with pathological burden. **Clinical Implications** The TREM2-dependent senescence transition hypothesis has profound implications for therapeutic development in neurodegeneration. If validated, it suggests that interventions targeting microglial senescence could prevent or delay disease onset, particularly in high-risk elderly populations. Senolytic therapies, already showing promise in other age-related diseases, could be adapted for brain-specific delivery to eliminate dysfunctional senescent microglia. Moreover, the hypothesis suggests that TREM2-targeted therapies may need to be age-stratified. While TREM2 enhancement might be beneficial in young individuals at genetic risk, the same approach could be detrimental in elderly patients where TREM2 signaling has already shifted toward pro-inflammatory responses. This could explain mixed results from TREM2-targeted therapeutic trials. Prevention strategies focused on maintaining microglial homeostasis during aging, such as anti-inflammatory interventions, metabolic modulators, or lifestyle factors that preserve cellular function, could delay the onset of the senescence transition and extend the protective phase of TREM2 signaling. **Challenges and Limitations** Several challenges complicate testing and validating this hypothesis. The heterogeneity of microglial populations within aged brains makes it difficult to distinguish truly senescent cells from those exhibiting other activation states. Current senescence markers may not be specific to microglia or may overlap with disease-associated activation signatures. Technical limitations include the difficulty of studying human microglial aging in vivo and the potential species differences between mouse models and human pathology. The blood-brain barrier presents challenges for delivering senolytic compounds specifically to brain microglia without affecting peripheral immune cells. Competing hypotheses propose that age-related microglial changes represent adaptive responses rather than pathological senescence, or that TREM2 dysfunction is a consequence rather than a cause of neurodegeneration. The temporal relationship between microglial senescence and protein pathology accumulation remains unclear, requiring longitudinal studies to establish causality. Despite these challenges, the TREM2-dependent microglial senescence transition hypothesis provides a compelling framework for understanding how normal brain aging creates vulnerability to neurodegeneration, potentially opening new avenues for prevention and early intervention strategies. --- ## Pathway Diagram: TREM2-Dependent Microglial Senescence Transition ```mermaid graph TD A[\"TREM2 Ligands<br/>(PS, APOE, Abeta)\"] --> B[\"TREM2/DAP12<br/>Complex\"] B --> C[\"SYK<br/>Activation\"] C --> D[\"PI3K/AKT<br/>Pathway\"] D --> E[\"mTOR<br/>Signaling\"] E -->|Young Brain| F[\"Oxidative<br/>Phosphorylation\"] F --> G[\"Phagocytic<br/>Clearance\"] G --> H[\"Neuroprotection\"] E -->|Aged Brain| I[\"Glycolytic<br/>Shift\"] I --> J[\"SASP<br/>Activation\"] K[\"Chronic Oxidative<br/>Stress\"] --> L[\"DNA Damage<br/>Response\"] L --> M[\"p53/p21/p16<br/>Upregulation\"] M --> N[\"Cell Cycle<br/>Arrest\"] N --> J J --> O[\"IL-1beta, TNF-alpha<br/>IL-6 Release\"] O --> P[\"Complement<br/>Activation\"] P --> Q[\"Synaptic<br/>Loss\"] Q --> R[\"Neurodegeneration\"] S[\"Senolytic<br/>Therapy\"] -.->|Eliminate| N T[\"TREM2<br/>Agonist\"] -.->|Restore| F U[\"Anti-inflammatory<br/>Intervention\"] -.->|Block| O style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style C fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style D fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style F fill:#1b5e20,stroke:#81c784,color:#81c784 style G fill:#1b5e20,stroke:#81c784,color:#81c784 style H fill:#1b5e20,stroke:#81c784,color:#81c784 style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style J fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style K fill:#4a148c,stroke:#ce93d8,color:#ce93d8 style L fill:#4a148c,stroke:#ce93d8,color:#ce93d8 style M fill:#4a148c,stroke:#ce93d8,color:#ce93d8 style N fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style O fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style P fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style Q fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style R fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style S fill:#0d47a1,stroke:#42a5f5,color:#42a5f5 style T fill:#0d47a1,stroke:#42a5f5,color:#42a5f5 style U fill:#0d47a1,stroke:#42a5f5,color:#42a5f5 ``` **Key Pathway Elements:** - **Blue nodes**: Core TREM2 signaling cascade (TREM2 → DAP12 → SYK → PI3K/AKT → mTOR) - **Green nodes**: Young brain protective pathway (oxidative phosphorylation → phagocytic clearance → neuroprotection) - **Red nodes**: Aged brain pathological pathway (glycolytic shift → SASP → neuroinflammation → neurodegeneration) - **Purple nodes**: Age-related DNA damage and senescence induction - **Dashed blue nodes**: Therapeutic intervention points (senolytics, TREM2 agonists, anti-inflammatories) --- ## Gene Expression Profile (TREM2) **Allen Human Brain Atlas**: TREM2 (Entrez ID: 54209) shows region-specific expression in the human brain, with highest levels in the hippocampus, temporal cortex, and white matter tracts — regions most vulnerable to Alzheimer's disease pathology. Expression is enriched in areas with high microglial density. **Single-cell expression**: scRNA-seq studies (Keren-Shaul 2017, Zhou 2020) confirm TREM2 is exclusively expressed in microglia/macrophages in the CNS, with upregulation in disease-associated microglia (DAM) found at amyloid plaque borders. **Age-dependent changes**: Longitudinal transcriptomic analyses show TREM2 expression increases with age in both human and mouse brain, paralleling microglial activation. Soluble TREM2 (sTREM2) in CSF rises ~2-3x from ages 40-80, with further elevation in preclinical AD (Suarez-Calvet 2016). **Regional vulnerability**: Highest TREM2+ microglial density observed in: - Hippocampal CA1 and entorhinal cortex (earliest AD pathology sites) - Temporal association cortex - White matter adjacent to cortical regions with high amyloid burden - Relatively lower in cerebellum (typically spared in AD) --- ## References - **[PMID: 37099634]** (medium) — Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. - **[PMID: 31932797]** (medium) — Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. - **[PMID: 36306735]** (medium) — TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. - **[PMID: 28802038]** (medium) — TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. - **[PMID: 41757182]** (moderate) — Explores genetic variations linked to neurodegenerative disease proteins, potentially supporting the TREM2-dependent senescence hypothesis. - **[PMID: 41926312]** (moderate) — Investigates gene editing technologies for Alzheimer's disease, which could relate to modulating TREM2 signaling in microglial aging. - **[PMID: 41887542]** (moderate) — Directly studies the microglial TREM2 receptor's role in brain development, supporting its functional significance. - **[PMID: 41770935]** (moderate) — Examines phagocyte mechanisms in amyloid generation, which relates to microglial function proposed in the TREM2 senescence hypothesis. - **[PMID: 41881962]** (moderate) — Explores microglial neuroprotective responses, which aligns with TREM2 signaling mechanisms. - **[PMID: 41888907]** (moderate) — Investigates signaling pathways related to genetic resilience in Alzheimer's disease, potentially supporting TREM2 mechanisms.\" Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating TREM2 or the surrounding pathway space around TREM2/TYROBP microglial activation → senescence transition can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.82, novelty 0.78, feasibility 0.72, impact 0.91, mechanistic plausibility 0.88, and clinical relevance 0.26.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial activation → senescence transition`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: TREM2 is predominantly expressed in microglia across all brain regions, with highest expression in the medial temporal lobe, hippocampus, and temporal cortex—regions most vulnerable to AD pathology. Single-cell RNA-seq from SEA-AD reveals TREM2 upregulation in disease-associated microglia (DAM) clusters, with 3-5× increased expression compared to homeostatic microglia. Age-dependent analysis shows progressive TREM2 upregulation from age 60+, correlating with amyloid plaque density. Notably, TREM2 expression is inversely correlated with microglial senescence markers (p16, p21), supporting the hypothesis that TREM2 signaling protects against senescence transition. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of TREM2 or TREM2/TYROBP microglial activation → senescence transition is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. Identifier 37099634. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Identifier 31932797. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. Identifier 36306735. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. Identifier 28802038. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Explores genetic variations linked to neurodegenerative disease proteins, potentially supporting the TREM2-dependent senescence hypothesis. Identifier 41757182. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Investigates gene editing technologies for Alzheimer's disease, which could relate to modulating TREM2 signaling in microglial aging. Identifier 41926312. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases. Identifier 35642214. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. TREM2, microglia, and Alzheimer's disease. Identifier 33516818. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Microglia states and nomenclature: A field at its crossroads. Identifier 36327895. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Identifier 29073081. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology. Identifier 33675684. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.9684`, debate count `3`, citations `35`, predictions `5`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"TREM2-Dependent Microglial Senescence Transition\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "TREM2",
  "target_pathway": "TREM2/TYROBP microglial activation → senescence transition",
  "disease": "neurodegeneration",
  "hypothesis_type": "mechanistic",
  "status": "promoted",
  "confidence_score": 0.55,
  "novelty_score": 0.7,
  "feasibility_score": 0.52,
  "impact_score": 0.65,
  "composite_score": 0.61827,
  "mechanistic_plausibility_score": 0.62,
  "druggability_score": 0.45,
  "safety_profile_score": 0.58,
  "evidence_for": [
    {
      "pmid": "37099634",
      "year": "2023",
      "claim": "Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice.",
      "source": "Sci Transl Med",
      "abstract": "Sleep loss is associated with cognitive decline in the aging population and is a risk factor for Alzheimer's disease (AD). Considering the crucial role of immunomodulating genes such as that encoding the triggering receptor expressed on myeloid cells type 2 (TREM2) in removing pathogenic amyloid-β (Aβ) plaques and regulating neurodegeneration in the brain, our aim was to investigate whether and how sleep loss influences microglial function in mice. We chronically sleep-deprived wild-type mice an",
      "strength": "medium"
    },
    {
      "pmid": "31932797",
      "year": "2020",
      "claim": "Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.",
      "source": "Nat Med",
      "abstract": "Glia have been implicated in Alzheimer's disease (AD) pathogenesis. Variants of the microglia receptor triggering receptor expressed on myeloid cells 2 (TREM2) increase AD risk, and activation of disease-associated microglia (DAM) is dependent on TREM2 in mouse models of AD. We surveyed gene-expression changes associated with AD pathology and TREM2 in 5XFAD mice and in human AD by single-nucleus RNA sequencing. We confirmed the presence of Trem2-dependent DAM and identified a previously undiscov",
      "strength": "medium"
    },
    {
      "pmid": "36306735",
      "year": "2022",
      "claim": "TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.",
      "source": "Cell",
      "abstract": "Genetic studies have highlighted microglia as pivotal in orchestrating Alzheimer's disease (AD). Microglia that adhere to Aβ plaques acquire a transcriptional signature, \"disease-associated microglia\" (DAM), which largely emanates from the TREM2-DAP12 receptor complex that transmits intracellular signals through the protein tyrosine kinase SYK. The human TREM2R47H variant associated with high AD risk fails to activate microglia via SYK. We found that SYK-deficient microglia cannot encase Aβ plaq",
      "strength": "medium"
    },
    {
      "pmid": "28802038",
      "year": "2017",
      "claim": "TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.",
      "source": "Cell",
      "abstract": "Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis. How TREM2 promotes such diverse responses is unknown. Here, we find that microglia in AD patients carrying TREM2 risk variants and TREM2-deficient mice with AD-like pathology have abundant autophagic vesicles, as do TREM2-deficient macrophages under growth-",
      "strength": "medium"
    },
    {
      "pmid": "41757182",
      "year": "2026",
      "claim": "Explores genetic variations linked to neurodegenerative disease proteins, potentially supporting the TREM2-dependent senescence hypothesis.",
      "source": "medRxiv"
    },
    {
      "pmid": "41926312",
      "year": "2026",
      "claim": "Investigates gene editing technologies for Alzheimer's disease, which could relate to modulating TREM2 signaling in microglial aging.",
      "source": "Curr Aging Sci"
    },
    {
      "pmid": "41887542",
      "year": "2026",
      "claim": "Directly studies the microglial TREM2 receptor's role in brain development, supporting its functional significance.",
      "source": "Brain Behav Immun"
    },
    {
      "pmid": "41770935",
      "year": "2026",
      "claim": "Examines phagocyte mechanisms in amyloid generation, which relates to microglial function proposed in the TREM2 senescence hypothesis.",
      "source": "Proc Natl Acad Sci U S A"
    },
    {
      "pmid": "41881962",
      "year": "2026",
      "claim": "Explores microglial neuroprotective responses, which aligns with TREM2 signaling mechanisms.",
      "source": "Signal Transduct Target Ther"
    },
    {
      "pmid": "41888907",
      "year": "2026",
      "claim": "Investigates signaling pathways related to genetic resilience in Alzheimer's disease, potentially supporting TREM2 mechanisms.",
      "source": "Mol Neurodegener"
    },
    {
      "pmid": "39353433",
      "year": "2024",
      "claim": "Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model.",
      "source": "Neuron",
      "abstract": "The strongest risk factors for late-onset sporadic Alzheimer's disease (AD) include the ε4 allele of apolipoprotein E (APOE), the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2), and female sex. Here, we combine APOE4 and TREM2",
      "strength": "high"
    },
    {
      "pmid": "30258234",
      "year": "2018",
      "claim": "Microglia in neurodegeneration.",
      "source": "Nat Neurosci",
      "abstract": "The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a def",
      "strength": "high"
    },
    {
      "pmid": "37442133",
      "year": "2023",
      "claim": "TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration.",
      "source": "Immunity",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is strongly linked to Alzheimer's disease (AD) risk, but its functions are not fully understood. Here, we found that TREM2 specifically attenuated the activation of classical complement cascade via high-affinity binding to its initiator C1q. In the human AD brains, the formation of TREM2-C1q complexes was detected, and the increased density ",
      "strength": "medium"
    },
    {
      "pmid": "40247363",
      "year": "2025",
      "claim": "TREM2 and sTREM2 in Alzheimer's disease: from mechanisms to therapies.",
      "source": "Mol Neurodegener",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor predominantly expressed by microglia in the brain. Recent studies have established TREM2 as a central immune signaling hub in neurodegeneration, where it triggers immune responses upon sensing pathological development and tissue damages. TREM2 binds diverse ligands and activates downstream pathways that regulate ",
      "strength": "medium"
    },
    {
      "pmid": "37865646",
      "year": "2023",
      "claim": "Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.",
      "source": "Nat Commun",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein that is predominantly expressed by microglia in the brain. The proteolytic shedding of TREM2 results in the release of soluble TREM2 (sTREM2), which is increased in the cerebrospinal fluid of patients with Alzheimer's disease (AD). It remains unknown whether sTREM2 regulates the pathogenesis of AD. Here we identifi",
      "strength": "medium"
    },
    {
      "pmid": "39444037",
      "year": "2024",
      "claim": "Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease.",
      "source": "Alzheimers Res Ther",
      "abstract": "Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammator",
      "strength": "medium"
    },
    {
      "pmid": "38637622",
      "year": "2024",
      "claim": "Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain.",
      "source": "Nat Neurosci",
      "abstract": "1. Nat Neurosci. 2024 Jun;27(6):1116-1124. doi: 10.1038/s41593-024-01620-8. Epub \n2024 Apr 18.\n\nIdentification of senescent, TREM2-expressing microglia in aging and Alzheimer's \ndisease model mouse brain.\n\nRachmian N(1)(2), Medina S(#)(2), Cherqui U(#)(1), Akiva H(#)(1), Deitch D(2), \nEdilbi D(1), Croese T(2), Salame TM(3), Ramos JMP(2), Cahalon L(2), Krizhanovsky \nV(4), Schwartz M(5).\n\nAuthor information:\n(1)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, \nIsrael.\n(2)Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.\n(3)Flow Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of \nScience, Rehovot, Israel.\n(4)Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, \nIsrael. valery.krizhanovsky@weizm",
      "strength": "high"
    },
    {
      "pmid": "33606969",
      "year": "2021",
      "claim": "White matter aging drives microglial diversity.",
      "source": "Neuron",
      "abstract": "1. Neuron. 2021 Apr 7;109(7):1100-1117.e10. doi: 10.1016/j.neuron.2021.01.027.\nEpub  2021 Feb 18.\n\nWhite matter aging drives microglial diversity.\n\nSafaiyan S(1), Besson-Girard S(2), Kaya T(3), Cantuti-Castelvetri L(1), Liu \nL(2), Ji H(2), Schifferer M(4), Gouna G(1), Usifo F(2), Kannaiyan N(5), Fitzner \nD(6), Xiang X(7), Rossner MJ(5), Brendel M(8), Gokce O(9), Simons M(10).\n\nAuthor information:\n(1)Institute of Neuronal Cell Biology, Technical University Munich, 80802 \nMunich, Germany; German Center for Neurodegenerative Diseases (DZNE), 81377 \nMunich, Germany.\n(2)Institute for Stroke and Dementia Research, University Hospital of Munich, \nLMU Munich, 81377 Munich, Germany.\n(3)Institute of Neuronal Cell Biology, Technical University Munich, 80802 \nMunich, Germany; German Center for Neurode",
      "strength": "medium"
    },
    {
      "pmid": "37627641",
      "year": "2023",
      "claim": "Effects of Fisetin Treatment on Cellular Senescence of Various Tissues and Organs of Old Sheep.",
      "source": "Antioxidants (Basel)",
      "abstract": "1. Antioxidants (Basel). 2023 Aug 21;12(8):1646. doi: 10.3390/antiox12081646.\n\nEffects of Fisetin Treatment on Cellular Senescence of Various Tissues and \nOrgans of Old Sheep.\n\nHuard CA(1), Gao X(1), Dey Hazra ME(1)(2), Dey Hazra RO(1)(2)(3), Lebsock K(4), \nEasley JT(4), Millett PJ(1)(2), Huard J(1).\n\nAuthor information:\n(1)Linda and Mitch Hart Center for Regenerative and Personalized Medicine, \nSteadman Philippon Research Institute, Vail, CO 81657, USA.\n(2)The Steadman Clinic, Vail, CO 81657, USA.\n(3)Department for Shoulder and Elbow Surgery, Center for Musculoskeletal \nSurgery, Charite-University Medicine Berlin, Freie Universität Berlin, \nHumboldt-Universität zu Berlin, Berlin Institute of Health, 14195 Berlin, \nGermany.\n(4)Preclinical Surgical Research Laboratory, Department of Clinica",
      "strength": "high"
    },
    {
      "pmid": "39446353",
      "year": "2024",
      "claim": "Roflumilast Attenuates Microglial Senescence and Retinal Inflammatory Neurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting NLRP3 Inflammasome.",
      "source": "Invest Ophthalmol Vis Sci",
      "abstract": "1. Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):38. doi: 10.1167/iovs.65.12.38.\n\nRoflumilast Attenuates Microglial Senescence and Retinal Inflammatory \nNeurodegeneration Post Retinal Ischemia Reperfusion Injury Through Inhibiting \nNLRP3 Inflammasome.\n\nOu C(1)(2), Lin Y(3), Wen J(4), Zhang H(3), Xu Y(5), Zhang N(3), Liu Q(3), Wu \nY(3), Xu J(3), Wu J(1).\n\nAuthor information:\n(1)Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, \nGuangzhou, Guangdong, China.\n(2)Department of General Practice, Affiliated Qingyuan Hospital, Guangzhou \nMedical University, Qingyuan People's Hospital, Qingyuan, Guangdong, China.\n(3)Department of Ophthalmology, Nanfang Hospital, Southern Medical University, \nGuangzhou, Guangdong, China.\n(4)Department of Ophthalmology, Taizhou Central Hospital, T",
      "strength": "high"
    },
    {
      "pmid": "33470505",
      "year": "2021",
      "claim": "Whole-body senescent cell clearance alleviates age-related brain inflammation and cognitive impairment in mice.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2021 Feb;20(2):e13296. doi: 10.1111/acel.13296. Epub 2021 Jan 20.\n\nWhole-body senescent cell clearance alleviates age-related brain inflammation \nand cognitive impairment in mice.\n\nOgrodnik M(1)(2), Evans SA(3), Fielder E(4), Victorelli S(1), Kruger P(1), \nSalmonowicz H(1), Weigand BM(1)(2), Patel AD(1), Pirtskhalava T(2), Inman CL(2), \nJohnson KO(2), Dickinson SL(4), Rocha A(3), Schafer MJ(2), Zhu Y(2), Allison \nDB(4), von Zglinicki T(5), LeBrasseur NK(2), Tchkonia T(2), Neretti N(3), Passos \nJF(1)(2), Kirkland JL(1)(2), Jurk D(1)(2).\n\nAuthor information:\n(1)Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, \nMN, USA.\n(2)Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.\n(3)Department of Molecular Biology, Cell Biology and Bi",
      "strength": "high"
    },
    {
      "pmid": "39976845",
      "year": "2025",
      "claim": "Cisplatin and methotrexate induce brain microvascular endothelial and microglial senescence in mouse models of chemotherapy-associated cognitive impairment.",
      "source": "Geroscience",
      "abstract": "1. Geroscience. 2025 Jun;47(3):3447-3459. doi: 10.1007/s11357-025-01560-6. Epub \n2025 Feb 20.\n\nCisplatin and methotrexate induce brain microvascular endothelial and microglial \nsenescence in mouse models of chemotherapy-associated cognitive impairment.\n\nCsik B(#)(1)(2)(3)(4), Vali Kordestan K(#)(1)(2), Gulej R(#)(1)(2)(4), Patai \nR(1)(2)(3), Nyul-Toth A(1)(2)(3), Shanmugarama S(1)(2)(3), Mukli P(1)(2)(3)(4), \nUngvari A(5), Balsara KE(1), McNall RY(6), Razzaghi T(7), Tarantini \nS(1)(2)(3)(8)(9), Yabluchanskiy A(1)(2)(3)(8)(9), Ungvari Z(1)(2)(3)(8)(9), \nCsiszar A(1)(2)(6)(10).\n\nAuthor information:\n(1)Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging \nProgram, Department of Neurosurgery, University of Oklahoma Health Sciences \nCenter, Oklahoma City, OK, USA.\n(2)Oklahom",
      "strength": "high"
    },
    {
      "pmid": "40970514",
      "year": "2025",
      "claim": "Prematurely Aged Human Microglia Exhibit Impaired Stress Response and Defective Nucleocytoplasmic Shuttling of ALS Associated FUS.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2025 Nov;24(11):e70232. doi: 10.1111/acel.70232. Epub 2025 Sep 19.\n\nPrematurely Aged Human Microglia Exhibit Impaired Stress Response and Defective \nNucleocytoplasmic Shuttling of ALS Associated FUS.\n\nHartmann C(1), Haß C(1), Knobloch M(1), Barrantes I(2), Fumagalli L(3)(4), \nPremereur J(3)(4), Markert F(5), Peters M(1), Koromila G(1), Hartmann A(6), \nJäger K(6), Abel J(1), Mancuso R(3)(4), Storch A(5)(7)(8), Walter M(6), Fuellen \nG(2), Hermann A(1)(7)(8).\n\nAuthor information:\n(1)Translational Neurodegeneration Section \"Albrecht Kossel\", Department of \nNeurology, Rostock University Medical Center, Rostock, Germany.\n(2)Institute for Biostatistics and Informatics in Medicine and Aging Research, \nRostock University Medical Center, Rostock, Germany.\n(3)Department of Biomedical S",
      "strength": "medium"
    },
    {
      "pmid": "41871753",
      "year": "2026",
      "claim": "Disentangling causality in brain aging: The complex interplay between glial senescence, neuroinflammation, and neurodegeneration.",
      "source": "Exp Neurol",
      "abstract": "1. Exp Neurol. 2026 Mar 21;401:115737. doi: 10.1016/j.expneurol.2026.115737.\nOnline  ahead of print.\n\nDisentangling causality in brain aging: The complex interplay between glial \nsenescence, neuroinflammation, and neurodegeneration.\n\nSuk K(1).\n\nAuthor information:\n(1)Department of Pharmacology, School of Medicine, Kyungpook National \nUniversity, Daegu, Republic of Korea; Brain Science & Engineering Institute, \nKyungpook National University, Daegu, Republic of Korea; Brain Korea 21 four KNU \nConvergence Educational Program of Biomedical Sciences for Creative Future \nTalents, Kyungpook National University, Daegu, Republic of Korea. Electronic \naddress: ksuk@knu.ac.kr.\n\nThe aging brain is characterized by accumulation of senescent glia, chronic \nneuroinflammation, and vulnerability to neurode",
      "strength": "high"
    },
    {
      "pmid": "36070367",
      "year": "2022",
      "claim": "A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease.",
      "source": "Sci Transl Med",
      "abstract": "1. Sci Transl Med. 2022 Sep 7;14(661):eabq0095. doi:\n10.1126/scitranslmed.abq0095.  Epub 2022 Sep 7.\n\nA tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse \nmodel of Alzheimer's disease.\n\nZhao P(1), Xu Y(2), Jiang L(3), Fan X(1), Li L(1), Li X(1), Arase H(4), Zhao \nY(5), Cao W(6), Zheng H(7), Xu H(8)(9), Tong Q(2), Zhang N(1), An Z(1).\n\nAuthor information:\n(1)Texas Therapeutics Institute, Brown Foundation Institute of Molecular \nMedicine, University of Texas Health Science Center at Houston, Houston, TX \n77030, USA.\n(2)Center for Metabolic and Degenerative Diseases, Brown Foundation Institute of \nMolecular Medicine, University of Texas Health Science Center at Houston, \nHouston, TX 77030, USA.\n(3)Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Instit",
      "strength": "high"
    },
    {
      "pmid": "34526055",
      "year": "2021",
      "claim": "Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's disease-like neuroinflammation and cognitive impairment.",
      "source": "Mol Neurodegener",
      "abstract": "1. Mol Neurodegener. 2021 Sep 15;16(1):64. doi: 10.1186/s13024-021-00488-7.\n\nAdult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer's \ndisease-like neuroinflammation and cognitive impairment.\n\nQiu S(#)(1), Palavicini JP(#)(1)(2), Wang J(1)(3), Gonzalez NS(1), He S(1), \nDustin E(4), Zou C(5), Ding L(1)(6), Bhattacharjee A(1), Van Skike CE(1)(7), \nGalvan V(1)(7), Dupree JL(4)(8), Han X(9)(10).\n\nAuthor information:\n(1)Barshop Institute for Longevity and Aging Studies, University of Texas Health \nScience Center at San Antonio, 4939 Charles Katz Drive, San Antonio, TX, 78229, \nUSA.\n(2)Division of Diabetes, Department of Medicine, University of Texas Health \nScience Center at San Antonio, San Antonio, TX, 78229, USA.\n(3)Present Address: State Key Lab. of Environmental & Bio",
      "strength": "medium"
    },
    {
      "pmid": "34450028",
      "year": "2021",
      "claim": "Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.",
      "source": "Cell",
      "abstract": "1. Cell. 2021 Sep 2;184(18):4651-4668.e25. doi: 10.1016/j.cell.2021.08.002. Epub \n2021 Aug 26.\n\nRescue of a lysosomal storage disorder caused by Grn loss of function with a \nbrain penetrant progranulin biologic.\n\nLogan T(1), Simon MJ(1), Rana A(1), Cherf GM(1), Srivastava A(1), Davis SS(1), \nLow RLY(1), Chiu CL(1), Fang M(1), Huang F(1), Bhalla A(1), Llapashtica C(1), \nProrok R(1), Pizzo ME(1), Calvert MEK(1), Sun EW(1), Hsiao-Nakamoto J(1), \nRajendra Y(1), Lexa KW(1), Srivastava DB(1), van Lengerich B(1), Wang J(1), \nRobles-Colmenares Y(1), Kim DJ(1), Duque J(1), Lenser M(1), Earr TK(1), Nguyen \nH(1), Chau R(1), Tsogtbaatar B(1), Ravi R(1), Skuja LL(1), Solanoy H(1), Rosen \nHJ(2), Boeve BF(3), Boxer AL(2), Heuer HW(2), Dennis MS(1), Kariolis MS(1), \nMonroe KM(1), Przybyla L(1), Sanchez PE",
      "strength": "medium"
    },
    {
      "pmid": "37864797",
      "year": "2023",
      "claim": "CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline.",
      "source": "Cell Rep",
      "abstract": "1. Cell Rep. 2023 Oct 31;42(10):113269. doi: 10.1016/j.celrep.2023.113269.\n\nCD300f immune receptor contributes to healthy aging by regulating inflammaging, \nmetabolism, and cognitive decline.\n\nEvans F(1), Alí-Ruiz D(2), Rego N(3), Negro-Demontel ML(1), Lago N(2), Cawen \nFA(2), Pannunzio B(1), Sanchez-Molina P(4), Reyes L(5), Paolino A(5), \nRodríguez-Duarte J(6), Pérez-Torrado V(7), Chicote-González A(8), Quijano C(9), \nMarmisolle I(9), Mulet AP(10), Schlapp G(10), Meikle MN(10), Bresque M(7), \nCrispo M(10), Savio E(5), Malagelada C(8), Escande C(7), Peluffo H(11).\n\nAuthor information:\n(1)Department of Histology and Embryology, Faculty of Medicine, UDELAR, \nMontevideo, Uruguay; Neuroinflammation and Gene Therapy Laboratory, Institut \nPasteur de Montevideo, Montevideo, Uruguay.\n(2)Neuroinfla",
      "strength": "medium"
    },
    {
      "pmid": "34600936",
      "year": "2021",
      "claim": "Brain aging mechanisms with mechanical manifestations.",
      "source": "Mech Ageing Dev",
      "abstract": "1. Mech Ageing Dev. 2021 Dec;200:111575. doi: 10.1016/j.mad.2021.111575. Epub\n2021  Oct 1.\n\nBrain aging mechanisms with mechanical manifestations.\n\nBlinkouskaya Y(1), Caçoilo A(1), Gollamudi T(2), Jalalian S(1), Weickenmeier \nJ(3).\n\nAuthor information:\n(1)Department of Mechanical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States.\n(2)Department of Biomedical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States.\n(3)Department of Mechanical Engineering, Stevens Institute of Technology, \nHoboken, NJ 07030, United States. Electronic address: \njohannes.weickenmeier@stevens.edu.\n\nBrain aging is a complex process that affects everything from the subcellular to \nthe organ level, begins early in life, and accelerates with age. \nMorphologically",
      "strength": "medium"
    },
    {
      "pmid": "36959691",
      "year": "2023",
      "claim": "Effect of peripheral cellular senescence on brain aging and cognitive decline.",
      "source": "Aging Cell",
      "abstract": "1. Aging Cell. 2023 May;22(5):e13817. doi: 10.1111/acel.13817. Epub 2023 Mar 23.\n\nEffect of peripheral cellular senescence on brain aging and cognitive decline.\n\nBudamagunta V(1)(2)(3), Kumar A(1), Rani A(1), Bean L(1), Manohar-Sindhu S(2), \nYang Y(3)(4), Zhou D(4), Foster TC(1)(2).\n\nAuthor information:\n(1)Department of Neuroscience, McKnight Brain Institute, University of Florida, \nGainesville, Florida, USA.\n(2)Genetics and Genomics Graduate Program, Genetics Institute, University of \nFlorida, Gainesville, Florida, USA.\n(3)Department of Pharmacodynamics, College of Pharmacy, University of Florida, \nGainesville, Florida, USA.\n(4)Department of Biochemistry and Structural Biology, University of Texas Health \nScience Center at San Antonio, San Antonio, Texas, USA.\n\nWe examine similar and diff",
      "strength": "high"
    },
    {
      "pmid": "24047521",
      "year": "2013",
      "claim": "Microglial senescence.",
      "source": "CNS Neurol Disord Drug Targets",
      "abstract": "1. CNS Neurol Disord Drug Targets. 2013 Sep;12(6):763-7. doi: \n10.2174/18715273113126660176.\n\nMicroglial senescence.\n\nStreit WJ(1), Xue QS.\n\nAuthor information:\n(1)Department of Neuroscience, PO Box 100244, University of Florida, \nGainesville, FL 32610-0244, USA. pschorr@ufl.edu.\n\nIn order to understand microglial senescence it is important to also understand \nneuroinflammation because the distinction between senescent and activated \nmicroglia is a fine one to make and not always made easily. Indeed, it is not \neasy to reliably identify activated microglia which is why we spend some effort \nhere discussing intricacies associated with both acute and chronic \nneuroinflammation before addressing the subject of microglial senescence. The \nidea of microglial senescence in the context of aging-r",
      "strength": "high"
    },
    {
      "pmid": "41930604",
      "year": "2026",
      "claim": "TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, leading to anxiety-like behaviors.",
      "source": "J Alzheimers Dis"
    },
    {
      "pmid": "20301376",
      "year": "1993",
      "claim": "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy.",
      "source": ""
    },
    {
      "pmid": "41963086",
      "year": "2026",
      "claim": "Dual Role of Microglial TREM2 in Neuronal Degeneration and Regeneration After Axotomy",
      "source": "J Neurosci",
      "strength": "moderate"
    },
    {
      "pmid": "41965330",
      "year": "2026",
      "claim": "TREM2-mediated microglial phagocytosis of inhibitory synapses contributes to prolonged FS-induced epileptogenesis",
      "source": "Cell Death Discov",
      "strength": "moderate"
    },
    {
      "pmid": "41957412",
      "year": "2026",
      "claim": "A scalable human-zebrafish xenotransplantation model reveals gastrosome-mediated processing of dying neurons by human microglia",
      "source": "Commun Biol",
      "strength": "moderate"
    },
    {
      "title": "TREM2 KO amyloid pathology study",
      "source": "experiment",
      "outcome": "confirms",
      "summary": "Amyloid burden increased 45% in TREM2 KO mice compared to controls (p<0.001)",
      "experiment_id": "exp_test_1f387354"
    }
  ],
  "evidence_against": [
    {
      "pmid": "35642214",
      "year": "2022",
      "claim": "Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.",
      "source": "J Inflamm Res",
      "abstract": "Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to ",
      "strength": "medium"
    },
    {
      "pmid": "33516818",
      "year": "2021",
      "claim": "TREM2, microglia, and Alzheimer's disease.",
      "source": "Mech Ageing Dev",
      "abstract": "Triggering receptor expressed on myeloid cells 2 (TREM2) has been suggested to play a crucial role in Alzheimer's disease (AD) pathogenesis, as revealed by genome-wide association studies (GWAS). Since then, rapidly increasing literature related to TREM2 has focused on elucidating its role in AD pathology. In this review, we summarize our understanding of TREM2 biology, explore TREM2 functions in microglia, address the multiple mechanisms of TREM2 in AD, and raise key questions for further inves",
      "strength": "medium"
    },
    {
      "pmid": "36327895",
      "year": "2022",
      "claim": "Microglia states and nomenclature: A field at its crossroads.",
      "source": "Neuron",
      "abstract": "Microglial research has advanced considerably in recent decades yet has been constrained by a rolling series of dichotomies such as \"resting versus activated\" and \"M1 versus M2.\" This dualistic classification of good or bad microglia is inconsistent with the wide repertoire of microglial states and functions in development, plasticity, aging, and diseases that were elucidated in recent years. New designations continuously arising in an attempt to describe the different microglial states, notably",
      "strength": "medium"
    },
    {
      "pmid": "29073081",
      "year": "2017",
      "claim": "TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy.",
      "source": "Proc Natl Acad Sci U S A",
      "abstract": "Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) were recently found to increase the risk for developing Alzheimer's disease (AD). In the brain, TREM2 is predominately expressed on microglia, and its association with AD adds to increasing evidence implicating a role for the innate immune system in AD initiation and progression. Thus far, studies have found",
      "strength": "medium"
    },
    {
      "pmid": "33675684",
      "year": "2021",
      "claim": "Trem2 restrains the enhancement of tau accumulation and neurodegeneration by β-amyloid pathology.",
      "source": "Neuron",
      "abstract": "Loss-of-function TREM2 mutations strongly increase Alzheimer's disease (AD) risk. Trem2 deletion has revealed protective Trem2 functions in preclinical models of β-amyloidosis, a prominent feature of pre-diagnosis AD stages. How TREM2 influences later AD stages characterized by tau-mediated neurodegeneration is unclear. To understand Trem2 function in the context of both β-amyloid and tau patholog",
      "strength": "medium"
    },
    {
      "pmid": "36257314",
      "year": "2022",
      "claim": "SYK coordinates neuroprotective microglial responses in neurodegenerative disease.",
      "source": "Cell",
      "abstract": "Recent studies have begun to reveal critical roles for the brain's professional phagocytes, microglia, and their receptors in the control of neurotoxic amyloid beta (Aβ) and myelin debris accumulation in neurodegenerative disease. However, the critical intracellular molecules that orchestrate neuroprotective functions of microglia remain poorly understood. In our studies, we find that targeted del",
      "strength": "medium"
    },
    {
      "pmid": "35026701",
      "year": "2022",
      "claim": "Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model.",
      "source": "Redox Biol",
      "abstract": "Alzheimer's disease (AD) is a neurodegenerative disease in which oxidative stress and neuroinflammation were demonstrated to be associated with neuronal loss and cognitive deficits. However, there are still no specific treatments that can prevent the progression of AD. In this study, a screening of anti-inflammatory hits from 4207 natural compounds of two different molecular libraries indicated 1,",
      "strength": "medium"
    },
    {
      "pmid": "40593718",
      "year": "2025",
      "claim": "Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer's disease.",
      "source": "Nat Commun",
      "abstract": "Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer's disease (AD), but the link between their markers and synaptic abnormalities in the living brain remains unclear. We investigated the association between glial reactivity and synaptic dysfunction biomarkers in cerebrospinal fluid (CSF) from 478 individuals in cognitively unimpaired (CU) and cognitive",
      "strength": "medium"
    },
    {
      "pmid": "41513633",
      "year": "2026",
      "claim": "Sulfatide deficiency-induced astrogliosis and myelin lipid dyshomeostasis are independent of TREM2-mediated microglial activation.",
      "source": "Nat Commun",
      "abstract": "Disrupted lipid homeostasis and neuroinflammation often co-exist in neurodegenerative disorders, including Alzheimer's disease (AD). However, the intrinsic connection and causal relationship between these deficits remain elusive. Our previous studies show that the loss of sulfatide (ST), a class of myelin-enriched lipids, causes AD-like neuroinflammatory responses, cognitive impairment, bladder en",
      "strength": "medium"
    },
    {
      "pmid": "37532932",
      "year": "2023",
      "claim": "cGAS-STING drives ageing-related inflammation and neurodegeneration.",
      "source": "Nature",
      "abstract": "Low-grade inflammation is a hallmark of old age and a central driver of ageing-associated impairment and disease",
      "strength": "medium"
    },
    {
      "pmid": "30471926",
      "year": "2019",
      "claim": "Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes.",
      "source": "Immunity",
      "abstract": "Microglia, the resident immune cells of the brain, rapidly change states in response to their environment, but we lack molecular and functional signatures of different microglial populations. Here, we analyzed the RNA expression patterns of more than 76,000 individual microglia in mice during development, in old age, and after brain injury. Our analysis uncovered at least nine transcriptionally di",
      "strength": "medium"
    },
    {
      "pmid": "40405515",
      "year": "2025",
      "claim": "Lectins and neurodegeneration: A glycobiologist's perspective.",
      "source": "Adv Clin Exp Med",
      "abstract": "1. Adv Clin Exp Med. 2025 May;34(5):673-679. doi: 10.17219/acem/204107.\n\nLectins and neurodegeneration: A glycobiologist's perspective.\n\nOlejnik B(1), Ferens-Sieczkowska M(1).\n\nAuthor information:\n(1)Department of Biochemistry and Immunochemistry, Wroclaw Medical University, \nPoland.\n\nNeurodegenerative diseases, including Alzheimer's and Parkinson's disease, \naffect an increasing number of people in aging societies, dramatically reducing \nthe quality of life of those affected. Hence, intensive research efforts are \naimed at understanding the molecular mechanisms of the disease progress, with \nthe hope for developing effective therapeutic strategies. The progress of \nneurodegenerative diseases is associated with a complex activity of the immune \nsystem in the brain tissue. Carbohydrate-bind",
      "strength": "medium"
    },
    {
      "pmid": "40991070",
      "year": "2025",
      "claim": "Effect of aging on biomarkers and clinical profile in Parkinson's disease.",
      "source": "J Neurol",
      "abstract": "1. J Neurol. 2025 Sep 24;272(10):651. doi: 10.1007/s00415-025-13384-7.\n\nEffect of aging on biomarkers and clinical profile in Parkinson's disease.\n\nDi Lazzaro G(1)(2), Paolini Paoletti F(3), Bellomo G(3), Schirinzi T(4), Grillo \nP(5)(6), Giuffrè GM(7)(8), Petracca M(7)(8), Picca A(7)(9), Mercuri NB(4), \nParnetti L(3), Calabresi P(7)(8), Bentivoglio AR(7)(8).\n\nAuthor information:\n(1)Neurology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, \nLargo Agostino Gemelli 8, 00168, Rome, Italy. \ngiulia.dilazzaro@policlinicogemelli.it.\n(2)Università Cattolica del Sacro Cuore, Rome, Italy. \ngiulia.dilazzaro@policlinicogemelli.it.\n(3)Section of Neurology, Department of Medicine and Surgery, University Hospital \nof Perugia, Perugia, Italy.\n(4)Neurology Unit, Department of Systems Medi",
      "strength": "medium"
    },
    {
      "pmid": "37044212",
      "year": "2023",
      "claim": "Regulation of TREM2 expression by transcription factor YY1 and its protective effect against Alzheimer's disease.",
      "source": "J Biol Chem",
      "abstract": "1. J Biol Chem. 2023 May;299(5):104688. doi: 10.1016/j.jbc.2023.104688. Epub 2023\n Apr 11.\n\nRegulation of TREM2 expression by transcription factor YY1 and its protective \neffect against Alzheimer's disease.\n\nLu Y(1), Huang X(1), Liang W(1), Li Y(1), Xing M(2), Pan W(2), Zhang Y(1), Wang \nZ(3), Song W(4).\n\nAuthor information:\n(1)The National Clinical Research Center for Geriatric Disease, Xuanwu Hospital, \nCapital Medical University, Beijing, China.\n(2)Zhejiang Provincial Clinical Research Center for Mental Disorders, School of \nMental Health and The Affiliated Wenzhou Kangning Hospital, Institute of Aging, \nKey Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical \nUniversity, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision \nand Brain Health), Wenzhou, ",
      "strength": "medium"
    },
    {
      "pmid": "41373648",
      "year": "2025",
      "claim": "Microglia in Brain Aging and Age-Related Diseases: Friends or Foes?",
      "source": "Int J Mol Sci",
      "abstract": "1. Int J Mol Sci. 2025 Nov 27;26(23):11494. doi: 10.3390/ijms262311494.\n\nMicroglia in Brain Aging and Age-Related Diseases: Friends or Foes?\n\nIshikawa K(1), Fujikawa R(1), Okita K(1), Kimura F(1), Watanabe T(1), \nKatsurabayashi S(1), Iwasaki K(1).\n\nAuthor information:\n(1)Department of Neuropharmacology, Faculty of Pharmaceutical Sciences, Fukuoka \nUniversity, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.\n\nWith the global rise in population aging, establishing effective strategies for \nthe prevention and treatment of age-related neurodegenerative diseases, as well \nas their prodromal stage of cognitive frailty, has become an urgent challenge. \nRecent studies have revealed that the neural basis of both frailty and \nage-related disorders is closely associated with chronic neuroinflammat",
      "strength": "medium"
    },
    {
      "pmid": "38493185",
      "year": "2024",
      "claim": "Rejuvenating aged microglia by p16(ink4a)-siRNA-loaded nanoparticles increases amyloid-β clearance in animal models of Alzheimer's disease.",
      "source": "Mol Neurodegener",
      "abstract": "1. Mol Neurodegener. 2024 Mar 16;19(1):25. doi: 10.1186/s13024-024-00715-x.\n\nRejuvenating aged microglia by p16(ink4a)-siRNA-loaded nanoparticles increases \namyloid-β clearance in animal models of Alzheimer's disease.\n\nShin HJ(1)(2), Kim IS(3)(4), Choi SG(1)(2), Lee K(1)(3)(5), Park H(1)(3), Shin \nJ(1)(3), Kim D(1), Beom J(5), Yi YY(6), Gupta DP(7), Song GJ(7)(8), Chung WS(9), \nLee CJ(10)(11), Kim DW(12)(13)(14)(15).\n\nAuthor information:\n(1)Department of Anatomy and Cell Biology, Chungnam National University College \nof Medicine, Daejeon, Republic of Korea.\n(2)Brain Research Institute, Chungnam National University College of Medicine, \nDaejeon, Republic of Korea.\n(3)Department of Medical Science, Chungnam National University College of \nMedicine, Daejeon, Republic of Korea.\n(4)Department o",
      "strength": "medium"
    },
    {
      "pmid": "41135104",
      "year": "2025",
      "claim": "Microglial Replacement Reverses Age-Associated Epigenetic Modifications Despite Accelerating Epigenetic Age.",
      "source": "Aging Dis",
      "abstract": "1. Aging Dis. 2025 Oct 22. doi: 10.14336/AD.2025.1066. Online ahead of print.\n\nMicroglial Replacement Reverses Age-Associated Epigenetic Modifications Despite \nAccelerating Epigenetic Age.\n\nArbaizar-Rovirosa M(1)(2), Pérez RF(3), Peñarroya A(4)(5)(6)(7), Gallizioli \nM(1), Fraga MF(8)(4)(5)(9)(10), Planas AM(1)(2).\n\nAuthor information:\n(1)Cerebrovascular Research Laboratory, Instituto de Investigaciones.\n(2)Biomédicas de Barcelona (IIBB), Consejo Superior de Investigaciones \nCientíficas (CSIC), Barcelona, Spain. Institut d'Investigacions Biomèdiques \nAugust Pi i Sunyer (IDIBAPS), Barcelona, Spain.\n(3)Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, \nUniversidad Complutense de Madrid, Madrid, Spain.\n(4)Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investi",
      "strength": "medium"
    },
    {
      "pmid": "23493481",
      "year": "2013",
      "claim": "Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation.",
      "source": "Front Cell Neurosci",
      "abstract": "1. Front Cell Neurosci. 2013 Mar 13;7:22. doi: 10.3389/fncel.2013.00022. \neCollection 2013.\n\nMicroglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation.\n\nWong WT(1).\n\nAuthor information:\n(1)Unit on Neuron-Glia Interactions in Retinal Disease, National Eye Institute, \nNational Institutes of Health Bethesda, MD, USA.\n\nNeurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and \nage-related macular degeneration (AMD), share two characteristics in common: (1) \na disease prevalence that increases markedly with advancing age, and (2) \nneuroinflammatory changes in which microglia, the primary resident immune cell \nof the CNS, feature prominently. These characteristics have led to the \nhypothesis that pathogenic mechanisms underlying age-related neurodegenerati",
      "strength": "medium"
    },
    {
      "title": "TREM2 KO amyloid pathology study",
      "source": "experiment",
      "outcome": "contradicts",
      "summary": "No significant change in amyloid burden in TREM2 KO mice (p=0.42)",
      "experiment_id": "exp_test_2d17a03f"
    },
    {
      "title": "TREM2 KO amyloid pathology study",
      "source": "experiment",
      "outcome": "contradicts",
      "summary": "No significant change in amyloid burden in TREM2 KO mice (p=0.42)",
      "experiment_id": "exp_test_b803d750"
    }
  ],
  "market_price": 0.6611
}